Navigation Links
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Date:3/11/2009

New use for PEGINTRON(TM) and REBETOL(R) offers certain patients a second chance to achieve treatment success

KENILWORTH, N.J., March 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved new labeling for PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for treating chronic hepatitis C in patients 3 years of age and older with compensated liver disease. With approval of this expanded indication, PEGINTRON and REBETOL is the first and only pegylated interferon combination therapy approved in the United States that is not restricted to treatment-naive patients. Patients less likely to benefit from retreatment after failing a course of therapy include those with previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, or HCV genotype 1 infection. It is estimated that more than 100,000 patients in the United States failed prior treatment of their hepatitis C virus (HCV) infection, representing a large and growing patient population.

"With the FDA approval of PEGINTRON and REBETOL combination therapy for this new indication, U.S. physicians now have a treatment option that offers a second chance for success to certain patients who failed prior therapy," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "This approval further underscores Schering-Plough's leadership and long-term commitment to developing new treatment options and innovative therapies to meet the needs of patients with hepatitis C."

Data from the clinical study supporting the approval helped to define those patient groups most likely to respond to retreatment as well as those unlikely to respond. Overall, p
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 Isis Pharmaceuticals, ... data from three drugs in its lipid franchise were ... of Cardiology (ESC) Congress in Barcelona Spain ... antisense drugs designed to provide effective and safe therapeutic ... is composed of one commercialized drug and several other ...
(Date:9/2/2014)... , Switzerland , September ... receiving ISO 13485 accreditation, Sophia Genetics has become the ... clinical use of a Next Generation Sequencing (NGS) ... certification represents an important step in raising the ... and brings Sophia Genetics, world-leading Data Driven Medicine ...
(Date:9/2/2014)... Sept. 2, 2014  Sinovac Biotech Ltd. (NASDAQ: ... China , today announced that the Company,s management ... , Morgan Stanley Global Healthcare Conference, to be held ... 10, 2014. , Morgan Stanley Asia Pacific Healthcare Day, ... 11, 2014. , Aegis Healthcare & Technology Conference, to ...
Breaking Medicine Technology:Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 2Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 3Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 4Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 5Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing 2Sinovac to Participate in Upcoming Investor Conferences 2
... (Nasdaq: ANTH ), a biopharmaceutical company developing ... autoimmune disorders, will release its first quarter 2012 financial ... Anthera will host a conference call at 8:30 am ... Conference Call Access: Date: Friday, May 4, 2012 Time: 8:30 ...
... for Disease Control reports annual deaths involving opioid pain ... in the United States. In New York and North ... abusing prescription medications continues to rise, sparking attention amongst ... care for those suffering from pain. For these reasons, ...
Cached Medicine Technology:Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 2Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 3Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 4
(Date:9/2/2014)... NOVAtime Technology, Inc. ( http://www.novatime.com ), a forward-thinking ... Avon Health Center, a long-time NOVAtime 3000 customer ... Time and Attendance / Workforce Management solution ... the NT7000 . , Avon Health Center in ... nursing facility that provides short-term rehabilitation, long-term care, ...
(Date:9/2/2014)... “Harmonicas have been formally used in ... help people with COPD or asthma. At this ... says Dana Keller, PhD, co-inventor of the Pulmonica. ... much the same – improved health with the ... , The three approaches to harmonicas in healthcare ...
(Date:9/2/2014)... New York, NY (PRWEB) September 02, 2014 ... for women are long gone. But even though men shave ... an unhealthy appearance – rough and irritated skin isn’t inevitable, ... Advanced Dermatology P.C. , For decades, skin care ... years have witnessed a surge in men of all ages ...
(Date:9/2/2014)... September 02, 2014 AURO ... Canada announced today the expansion of its leadership team ... first Chief Financial Officer. Liang joins AURO in conjunction ... and will work closely with the operations, product management ... their cloud presence as well as ensuring effective internal ...
(Date:9/1/2014)... (PRWEB) September 02, 2014 BambooIndustry.com is ... products. The company is famous for its high quality ... the company has announced its new range of ... matter of fact, the company has confidence in the ... clients a huge selection of elegant bamboo items and ...
Breaking Medicine News(10 mins):Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 2Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Rough Isn’t Rugged in Men’s Skin: Dermatology specialist Dr. Joshua Fox with Advanced Dermatology PC offers tips on easy skin maintenance for men 2Health News:Rough Isn’t Rugged in Men’s Skin: Dermatology specialist Dr. Joshua Fox with Advanced Dermatology PC offers tips on easy skin maintenance for men 3Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 3Health News:BambooIndustry.com: Solid Bamboo Floors Provided At Discounted Rates 2
... VIAP ), a biotechnology company focused on the ... today that,James G. Stewart, senior vice president, chief financial ... Susquehanna Second Annual SIGnificant,Options in Healthcare on Tuesday, March ... in New York. Interested parties may access a live ...
... You know that the HPV (human,papillomavirus) vaccine ... there a,theoretical basis for exploring its use in ... 3-part CME Webcast, assesses this,and other issues associated ... from Sexuality, Reproduction and Menopause (SRM), a clinical,publication ...
... SOUTH SAN FRANCISCO, Calif., Feb. 26 Rigel,Pharmaceuticals, ... it has named,Daniel B. Magilavy, M.D. vice president ... Magilavy will be responsible for the direction and,oversight ... and related autoimmune disorders. Rigel,s R788, oral syk ...
... EntreMed, Inc.,(Nasdaq: ENMD ) a clinical-stage pharmaceutical ... inflammatory diseases, today,announced that James S. Burns, President ... at the Jesup & Lamont Emerging Growth Stock,Conference, ... Resort in,Orlando, Florida on Thursday, February 28, 2008. ...
... /Xinhua-PRNewswire-FirstCall/ -- China Nepstar,Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based on the number ... entered into a definitive agreement to,acquire all of ... by Ningbo New Century Medical Ltd. ("New Century") ...
... XI,AN, China, Feb. 26 /Xinhua-PRNewswire-FirstCall/ -- China,Bionanometer ... company,within the bionanometer industry, will soon introduce ... of scientific verification, research and experiments,on the ... "Anti-influenza Oral,Granules" and the "Influenza Partner.", ...
Cached Medicine News:Health News:Experts Delve Into Issues of HPV Vaccination 2Health News:Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research 2Health News:Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research 3Health News:EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference 2Health News:China Nepstar Chain Drugstore to Acquire 68 Drugstores from Ningbo New Century Medical Ltd. 2Health News:China Nepstar Chain Drugstore to Acquire 68 Drugstores from Ningbo New Century Medical Ltd. 3Health News:China Nepstar Chain Drugstore to Acquire 68 Drugstores from Ningbo New Century Medical Ltd. 4Health News:China Bionanometer Industries Corporation Announces New Products for China 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: